[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT02-01 Phase 0 clinical trials,,"},{"Key":"Keywords","Value":"Glioblastoma,PARP inhibitors,Pharmacokinetics,Pharmacodynamics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>N. Sanai<\/b><sup>1<\/sup>, Y.-W. Chang<sup>1<\/sup>, J. Jiang<sup>2<\/sup>, J. Molloy<sup>1<\/sup>, C. Pennington-Krygier<sup>1<\/sup>, J. Harmon<sup>1<\/sup>, A. Hong<sup>1<\/sup>, J. Wanebo<sup>1<\/sup>, W. Kennedy<sup>1<\/sup>, M. Garcia<sup>1<\/sup>, I. Barani<sup>1<\/sup>, W. Yoo<sup>1<\/sup>, A. Tovmasyan<sup>1<\/sup>, A.-C. Tien<sup>1<\/sup>, J. Li<sup>2<\/sup>, S. Mehta<sup>1<\/sup>; <br\/><sup>1<\/sup>Barrow Neurological Institute, Phoenix, AZ, <sup>2<\/sup>Karmanos Cancer Institute, Detroit, MI","CSlideId":"","ControlKey":"8c7029ce-c995-4e2a-8f01-88e72acbd698","ControlNumber":"10473","DisclosureBlock":"&nbsp;<b>N. Sanai, <\/b> None..<br><b>Y. Chang, <\/b> None..<br><b>J. Jiang, <\/b> None..<br><b>J. Molloy, <\/b> None..<br><b>C. Pennington-Krygier, <\/b> None..<br><b>J. Harmon, <\/b> None..<br><b>A. Hong, <\/b> None..<br><b>J. Wanebo, <\/b> None..<br><b>W. Kennedy, <\/b> None..<br><b>M. Garcia, <\/b> None..<br><b>I. Barani, <\/b> None..<br><b>W. Yoo, <\/b> None..<br><b>A. Tovmasyan, <\/b> None..<br><b>A. Tien, <\/b> None..<br><b>J. Li, <\/b> None..<br><b>S. Mehta, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11492","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT125","PresenterBiography":null,"PresenterDisplayName":"Nader Sanai, MD","PresenterKey":"8c605800-c354-4444-9d29-0ea492fa84a3","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT125. A phase 0\/2 &#8216;trigger&#8217; trial of pamiparib or olaparib plus radiotherapy in patients with newly-diagnosed or recurrent glioblastoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 0\/2 &#8216;trigger&#8217; trial of pamiparib or olaparib plus radiotherapy in patients with newly-diagnosed or recurrent glioblastoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Colorectal cancer,Vaccine,metastatic disease,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. Vadehra<\/b><sup>1<\/sup>, C. Janes<sup>1<\/sup>, R. Frascati<sup>1<\/sup>, M. Reid<sup>1<\/sup>, T. C. Ramos<sup>2<\/sup>, S. Mukherjee<sup>1<\/sup>, K. L. Monzón<sup>2<\/sup>, P. L. L. Alvárez<sup>2<\/sup>, O. S. Morales<sup>2<\/sup>, C. M. Pardillo<sup>3<\/sup>, C. Fountzilas<sup>1<\/sup>; <br\/><sup>1<\/sup>Roswell Park Comprehensive Cancer Center, Buffalo, NY, <sup>2<\/sup>Center for Molecular Immunology, Havana, Cuba, <sup>3<\/sup>I2 Alliance, Havana, Cuba","CSlideId":"","ControlKey":"a508ed5e-620e-44ce-aa6b-6c4630828405","ControlNumber":"10490","DisclosureBlock":"&nbsp;<b>D. Vadehra, <\/b> None..<br><b>C. Janes, <\/b> None..<br><b>R. Frascati, <\/b> None..<br><b>M. Reid, <\/b> None.&nbsp;<br><b>T. C. Ramos, <\/b> <br><b>CIM<\/b> Other, Author Declares No financial disclosures, however CIM manufactures CIMAvax.<br><b>S. Mukherjee, <\/b> None.&nbsp;<br><b>K. L. Monzón, <\/b> <br><b>CIM<\/b> Author declares no financial disclosures however CIM manufactures CIMAvax. <br><b>P. L. L. Alvárez, <\/b> <br><b>CIM<\/b> Other, Author declares no financial disclosures however CIM manufactures CIMAvax. <br><b>O. S. Morales, <\/b> <br><b>CIM<\/b> Author declares no financial disclosures however CIM manufactures CIMAvax. <br><b>C. M. Pardillo, <\/b> <br><b>I2 Alliance<\/b> Author declares no financial disclosures however I2 alliance is a joint venture with CIM for CIMAvax research.<br><b>C. Fountzilas, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11493","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT126","PresenterBiography":null,"PresenterDisplayName":"Deepak Vadehra, DO","PresenterKey":"b327d3b8-167b-49e2-acb8-4453139431b6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT126. A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Immuno-oncology,Cell & Gene therapy,Macrophages,Tumor microenvironment,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Francesca Farina<\/b><sup>1<\/sup>, Bernhard Gentner<sup>2<\/sup>, Gaetano Finocchiaro<sup>3<\/sup>, Marica Eoli<sup>4<\/sup>, Alessia Capotondo<sup>5<\/sup>, Elena Anghileri<sup>4<\/sup>, Matteo Barcella<sup>5<\/sup>, Valentina Brambilla<sup>6<\/sup>, Matteo Carrabba<sup>1<\/sup>, Valeria Cuccarini<sup>7<\/sup>, Quintino Giorgio D'alessandris<sup>8<\/sup>, Francesco DiMeco<sup>9<\/sup>, Valeria Ferla<sup>1<\/sup>, Paolo Ferroli<sup>9<\/sup>, Filippo Gagliardi<sup>10<\/sup>, Federico Legnani<sup>9<\/sup>, Stefania Mazzoleni<sup>6<\/sup>, Alessandro Olivi<sup>8<\/sup>, Roberto Pallini<sup>8<\/sup>, Marco Saini<sup>9<\/sup>, Luigi Naldini<sup>2<\/sup>, Carlo Russo<sup>11<\/sup>, Fabio Ciceri<sup>1<\/sup><br><br\/><sup>1<\/sup>Hematology and Bone Marrow Transplant Unit - San Raffaele Hospital – Milano, Milano, Italy,<sup>2<\/sup>San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milano, Italy,<sup>3<\/sup>Neuro-Oncology Unit - San Raffaele Hospital – Milano, Milano, Italy,<sup>4<\/sup>Neuro-Oncology Unit - Istituto Neurologico Carlo Besta – Milano, Milano, Italy,<sup>5<\/sup>San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) – Milano, Milano, Italy,<sup>6<\/sup>Genenta Science, Milano, Italy,<sup>7<\/sup>Neuroradiology Unit - Istituto Neurologico Carlo Besta – Milano, Milano, Italy,<sup>8<\/sup>Neurosurgery Unit - Policlinico Gemelli – Roma, Roma, Italy,<sup>9<\/sup>Neurosurgery Unit - Istituto Neurologico Carlo Besta – Milano, Milano, Italy,<sup>10<\/sup>Neurosurgery Unit - San Raffaele Hospital – Milano, Milano, Italy,<sup>11<\/sup>Genenta Science, New York, NY","CSlideId":"","ControlKey":"9a4ea815-9c27-44a6-b881-52b2a45a2760","ControlNumber":"9779","DisclosureBlock":"&nbsp;<b>F. Farina, <\/b> None.&nbsp;<br><b>B. Gentner, <\/b> <br><b>Genenta Science<\/b> Other, Founder, stockholder & consultant.<br><b>G. Finocchiaro, <\/b> None..<br><b>M. Eoli, <\/b> None..<br><b>A. Capotondo, <\/b> None..<br><b>E. Anghileri, <\/b> None..<br><b>M. Barcella, <\/b> None.&nbsp;<br><b>V. Brambilla, <\/b> <br><b>Genenta Science<\/b> Employment.<br><b>M. Carrabba, <\/b> None..<br><b>V. Cuccarini, <\/b> None..<br><b>Q. D'alessandris, <\/b> None..<br><b>F. DiMeco, <\/b> None..<br><b>V. Ferla, <\/b> None..<br><b>P. Ferroli, <\/b> None..<br><b>F. Gagliardi, <\/b> None..<br><b>F. Legnani, <\/b> None.&nbsp;<br><b>S. Mazzoleni, <\/b> <br><b>Genenta Science<\/b> Employment.<br><b>A. Olivi, <\/b> None..<br><b>R. Pallini, <\/b> None..<br><b>M. Saini, <\/b> None.&nbsp;<br><b>L. Naldini, <\/b> <br><b>Genenta Science<\/b> Other, Founder, stockholder & consultant. <br><b>C. Russo, <\/b> <br><b>Genenta Science<\/b> Employment.<br><b>F. Ciceri, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11494","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT127","PresenterBiography":"","PresenterDisplayName":"Alessia Capotondo, MD","PresenterKey":"e165a28d-e396-42e7-9fef-f14a32545983","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT127. A macrophages-based immunotherapy of solid tumors microenvironment: Preliminary results of the TEM-GBM_01 study","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A macrophages-based immunotherapy of solid tumors microenvironment: Preliminary results of the TEM-GBM_01 study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Triple-negative breast cancer (TNBC),AKT\/PKB activation,Immunotherapy,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"B. Xu<sup>1<\/sup>, P. Zhang<sup>1<\/sup>, Y. Wang<sup>2<\/sup>, Z. Tong<sup>3<\/sup>, T. Yao<sup>4<\/sup>, X. Wang<sup>5<\/sup>, Z. Wang<sup>6<\/sup>, P. Guo<sup>6<\/sup>, W. Ma<sup>6<\/sup>, <b>Y. YUE<\/b><sup>6<\/sup>; <br\/><sup>1<\/sup>Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, <sup>2<\/sup>Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou, China, <sup>3<\/sup>Tianjin Medical University Cancer Institute&Hospital, Tianjin, China, <sup>4<\/sup>The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, <sup>5<\/sup>Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China, <sup>6<\/sup>Laekna Therapeutics, Shanghai, China","CSlideId":"","ControlKey":"65ebfd4d-398d-4d9f-abeb-df90653206f1","ControlNumber":"10260","DisclosureBlock":"&nbsp;<b>B. Xu, <\/b> None..<br><b>P. Zhang, <\/b> None..<br><b>Y. Wang, <\/b> None..<br><b>Z. Tong, <\/b> None..<br><b>T. Yao, <\/b> None..<br><b>X. Wang, <\/b> None.&nbsp;<br><b>Z. Wang, <\/b> <br><b>Laekna Therapeutics<\/b> Employment. <br><b>P. Guo, <\/b> <br><b>Laekna Therapeutics<\/b> Employment. <br><b>W. Ma, <\/b> <br><b>Laekna Therapeutics<\/b> Employment. <br><b>Y. Yue, <\/b> <br><b>Laekna Therapeutics<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11495","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT128","PresenterBiography":null,"PresenterDisplayName":"Yong Yue, MD;PhD","PresenterKey":"25144b37-e2d3-4011-8275-5f049fd2be12","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT128. Phase I\/II clinical trials of LAE005, afuresertib plus nab-paclitaxel in patients with advanced solid tumors, primarily in patients with triple-negative breast cancer (TNBC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I\/II clinical trials of LAE005, afuresertib plus nab-paclitaxel in patients with advanced solid tumors, primarily in patients with triple-negative breast cancer (TNBC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"CAR T cells,Colorectal cancer,Adoptive cell therapy,Colorectal adenocarcinoma,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. P. Keenan<\/b><sup>1<\/sup>, C. H. Lieu<sup>2<\/sup>, M. Fakih<sup>3<\/sup>, D. Chen<sup>4<\/sup>, L. Lu<sup>5<\/sup>, E. Rowinsky<sup>5<\/sup>, V. Lu<sup>5<\/sup>, L. Xiao<sup>5<\/sup>, A. P. Venook<sup>1<\/sup>, B. Schlechter<sup>6<\/sup>; <br\/><sup>1<\/sup>UCSF - University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, <sup>2<\/sup>University of Colorado Cancer Center, Aurora, CO, <sup>3<\/sup>City of Hope Comprehensive Cancer Center, Duarte, CA, <sup>4<\/sup>Innovative Cellular Therapeutics, Shanghai, China, <sup>5<\/sup>Innovative Cellular Therapeutics, Rockville, MD, <sup>6<\/sup>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","CSlideId":"","ControlKey":"b08e8c59-e94a-4f6e-8748-45d8bb7ceefc","ControlNumber":"10430","DisclosureBlock":"<b>&nbsp;B. P. Keenan, <\/b> <br><b>Regeneron, Inc.<\/b> Other, consulting. <br><b>Roche\/Genentech<\/b> Grant\/Contract, Travel.<br><b>C. H. Lieu, <\/b> None.&nbsp;<br><b>M. Fakih, <\/b> <br><b>AbbVie, Inc.<\/b> Other, consultant. <br><b>AstraZeneca<\/b> Other, consultant. <br><b>Bayer Corporation<\/b> Other, Advisory, Consultant. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Other, Consultant, study drug provided to institution. <br><b>Eisai, Oncology<\/b> Other, Advisory Board. <br><b>Entos, Inc.<\/b> Other, Advisory Board. <br><b>Janssen<\/b> Other, Advisory Board. <br><b>Merck<\/b> Other, Advisory Board. <br><b>Mirati Therapeutics, Inc.<\/b> Other, Advisory Boards, Editorial Boards, Consulting. <br><b>Nouscom<\/b> Other, Advisory Board. <br><b>Pfizer<\/b> Other, Consulting. <br><b>Roche\/Genentech<\/b> Grant\/Contract, Other, Advisory Board. <br><b>Taiho Oncology<\/b> Other, Consulting. <br><b>AgenusBio<\/b> Grant\/Contract. <br><b>Verastem<\/b> Grant\/Contract. <br><b>D. Chen, <\/b> <br><b>Innovative Cellular Therapeutics<\/b> Employment. <br><b>L. Lu, <\/b> <br><b>Innovative Cellular Therapeutics<\/b> Employment. <br><b>E. Rowinsky, <\/b> <br><b>Innovative Cellular Therapeutics<\/b> Employment. <br><b>V. Lu, <\/b> <br><b>Innovative Cellular Therapeutics<\/b> Employment. <br><b>L. Xiao, <\/b> <br><b>Innovative Cellular Therapeutics<\/b> Employment.<br><b>A. P. Venook, <\/b> None..<br><b>B. Schlechter, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11496","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT129","PresenterBiography":null,"PresenterDisplayName":"Bridget Keenan, MD;PhD","PresenterKey":"ed736e25-cb91-4ef5-adbd-3ddef2b2d937","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT129. A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"IDO1,Colorectal cancer,Radiation therapy,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>H. Park<\/b><sup>1<\/sup>, K. Pedersen<sup>2<\/sup>, K. Huang<sup>2<\/sup>, M. Mutch<sup>2<\/sup>, H. Kim<sup>2<\/sup>, N. Trikalinos<sup>2<\/sup>, O. Aranha<sup>2<\/sup>, B. Tan<sup>2<\/sup>, R. Suresh<sup>2<\/sup>, L. Ratner<sup>2<\/sup>, M. Khushman<sup>2<\/sup>, J. Visconti<sup>2<\/sup>, K.-H. Lim<sup>2<\/sup>, L. Henke<sup>3<\/sup>, M. Swiecicki<sup>2<\/sup>, J. Liu<sup>2<\/sup>, P. Parikh<sup>4<\/sup>, M. Ciorba<sup>2<\/sup>; <br\/><sup>1<\/sup>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, <sup>2<\/sup>Washington University in St. Louis, St. Louis, MO, <sup>3<\/sup>Case Western Reserve University, Cleveland, OH, <sup>4<\/sup>Henry Ford Health Cancer, Detroit, MI","CSlideId":"","ControlKey":"de4891b0-4a46-46ec-a585-0379b13810a4","ControlNumber":"9732","DisclosureBlock":"<b>&nbsp;H. Park, <\/b> <br><b>Ambrx; Amgen; Aprea Therapeutics; Astra Zeneca; Bayer; BeiGene; BJ Bioscience; Bolt Biotherapeutics; Bristol-Myers Squibb; Daiichi Sankyo; Exelixis; Genentech;Gossamer Bio; ImmuneOncia; Incyte<\/b> Grant\/Contract. <br><b>Jounce Therapeutics; Lilly; MabSpace Biosciences; Macrogenics; Merck; Mersana; Mirati Therpeutics; Novartis; Oncologie; Pfizer; PsiOxus Therapeutics;Puma Biotechnology; Regeneron; Seagen<\/b> Grant\/Contract. <br><b>Strata Oncology; Synermore Biologics; Tizona Therapeutics; TopAlliance BioScience; Turning Point Therapeutics; Vedanta Biosciences<\/b> Grant\/Contract. <br><b>K. Pedersen, <\/b> <br><b>Bayer, Array BioPharma, Pfizer, Novartis, GlaxoSmithKline, SAGA Diagnostics, AstraZeneca, Taiho Oncology, Incyte, Artemida Pharma<\/b> Other, Consulting or Advisory Role. <br><b>WebMD<\/b> Other, Speaker's Bureau. <br><b>Merck, Abbvie, Roche\/Genentech, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, Lilly, Nouscom, Boston Biomedical, Rafael Pharmaceuticals, Novartis, Ipsen, Notera, Arcus, Incite, HCW Biologics<\/b> Grant\/Contract. <br><b>Cardiff Oncology, Biomea Fusion<\/b> Grant\/Contract. <br><b>Array BioPharma, BeiGene, Nouscom, GlaxoSmithKline<\/b> Travel.<br><b>K. Huang, <\/b> None..<br><b>M. Mutch, <\/b> None..<br><b>H. Kim, <\/b> None.&nbsp;<br><b>N. Trikalinos, <\/b> <br><b>Exelixis<\/b> Grant\/Contract.<br><b>O. Aranha, <\/b> None..<br><b>B. Tan, <\/b> None..<br><b>R. Suresh, <\/b> None..<br><b>L. Ratner, <\/b> None.&nbsp;<br><b>M. Khushman, <\/b> <br><b>Blueprint Medicines, Cardiff Oncology, Moderna Therapeutics, Regeneron<\/b> Stock. <br><b>Muerus, TriSalus Life Sciences, Cardinal Health<\/b> Other, Consulting or Advisory Role. <br><b>Caris Life Sciences<\/b> Other, Speaker's Bureau. <br><b>Abbvie, FOGPharma, IgM Biosciences<\/b> Grant\/Contract.<br><b>J. Visconti, <\/b> None.&nbsp;<br><b>K. Lim, <\/b> <br><b>Curis<\/b> Other, Honoraria. <br><b>L. Henke, <\/b> <br><b>Varian Medical Systems<\/b> Grant\/Contract.<br><b>M. Swiecicki, <\/b> None..<br><b>J. Liu, <\/b> None..<br><b>P. Parikh, <\/b> None.&nbsp;<br><b>M. Ciorba, <\/b> <br><b>Incyte<\/b> Grant\/Contract.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11497","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT130","PresenterBiography":null,"PresenterDisplayName":"Haeseong Park, MD;MPH","PresenterKey":"8ba995b7-708a-4c42-a071-0455fc9934a4","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT130. Epacadostat with preoperative chemoradiation in locally advanced rectal cancer (LARC): Results of a translational phase I clinical trial","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Epacadostat with preoperative chemoradiation in locally advanced rectal cancer (LARC): Results of a translational phase I clinical trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Pharmacokinetics,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Jang<\/b><sup>1<\/sup>, X. Wei<sup>1<\/sup>, X. Meng<sup>1<\/sup>, J. Reitano<sup>1<\/sup>, V. Urity<sup>1<\/sup>, C. Park<sup>1<\/sup>, B. Strickland<sup>1<\/sup>, G. Lee<sup>1<\/sup>, D. Nguyen<sup>2<\/sup>; <br\/><sup>1<\/sup>Elevar Therapeutics, Fort Lee, NJ, <sup>2<\/sup>Altasciences, Los Angeles, CA","CSlideId":"","ControlKey":"1f18071a-2ac2-4005-a576-d8ef3b5ea9c2","ControlNumber":"10288","DisclosureBlock":"<b>&nbsp;S. Jang, <\/b> <br><b>Elevar Therapeutics<\/b> Employment, Stock Option. <br><b>X. Wei, <\/b> <br><b>Elevar Therapeutics<\/b> Employment, Stock Option. <br><b>X. Meng, <\/b> <br><b>Elevar Therapeutics<\/b> Employment, Stock Option. <br><b>J. Reitano, <\/b> <br><b>Elevar Therapeutics<\/b> Employment, Stock Option. <br><b>V. Urity, <\/b> <br><b>Elevar Therapeutics<\/b> Employment, Stock Option. <br><b>C. Park, <\/b> <br><b>Elevar Therapeutics<\/b> Employment, Stock Option. <br><b>B. Strickland, <\/b> <br><b>Elevar Therapeutics<\/b> Employment, Stock Option. <br><b>G. Lee, <\/b> <br><b>Elevar Therapeutics<\/b> Employment, Stock Option.<br><b>D. Nguyen, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11498","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT131","PresenterBiography":null,"PresenterDisplayName":"Seong Jang, PhD","PresenterKey":"15cc910f-3aa3-42bb-bfce-11ac6b147f10","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT131. Effect of rivoceranib administered as 200 mg once daily on the pharmacokinetics of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 substrates","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Effect of rivoceranib administered as 200 mg once daily on the pharmacokinetics of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 substrates","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Gastrointestinal cancers: other,CLDN 18.2,OSEMITAMAB,Combination therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Janjigian<\/b><sup>1<\/sup>, A. Tolcher<sup>2<\/sup>, R. Mehta<sup>3<\/sup>, M. Cecchini<sup>4<\/sup>, B. Van Tine<sup>5<\/sup>, M. Kundranda<sup>6<\/sup>, A. Olatunji<sup>7<\/sup>, M. R. Patel<sup>8<\/sup>, J. Berlin<sup>9<\/sup>, C. Rocha-Lima<sup>10<\/sup>, D. Monga<sup>11<\/sup>, B. George<sup>12<\/sup>, A. Scott<sup>13<\/sup>, Z. Xia<sup>14<\/sup>, M. Elsafy<sup>15<\/sup>, E. Jones<sup>15<\/sup>, Z. Yao<sup>15<\/sup>, C. Qi<sup>14<\/sup>, C. Germa<sup>15<\/sup>, N. Gabrail<sup>16<\/sup>; <br\/><sup>1<\/sup>Memorial Sloan Kettering, New York, NY, <sup>2<\/sup>NEXT Oncology, San Antonio, TX, <sup>3<\/sup>Moffitt Cancer Center, Tampa, FL, <sup>4<\/sup>Yale Cancer Center, New Haven, CT, <sup>5<\/sup>Washington University, St. Louis, MO, <sup>6<\/sup>Banner MD Anderson Cancer Center, Phoenix, AZ, <sup>7<\/sup>Emory University, Atlanta, GA, <sup>8<\/sup>Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL, <sup>9<\/sup>Vanderbilt University Medical Center, Nashville, TN, <sup>10<\/sup>Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, <sup>11<\/sup>Allegheny Health Network Cancer Institute, Pittsburgh, PA, <sup>12<\/sup>Medical College of Wisconsin, Milwaukee, WI, <sup>13<\/sup>The University of Arizona Cancer Center, Tucson, AZ, <sup>14<\/sup>Transcenta Therapeutics Inc, Suzhou, China, <sup>15<\/sup>Transcenta Therapeutics Inc, Princeton, NJ, <sup>16<\/sup>Gabrail Cancer Center, Canton, OH","CSlideId":"","ControlKey":"8e3e1c48-4b67-4b1f-81e0-9b72981d0de6","ControlNumber":"10664","DisclosureBlock":"<b>&nbsp;Y. Janjigian, <\/b> <br><b>Astra Zeneca<\/b> Grant\/Contract, Other, Research Funding and Advisory Board\/Consulting. <br><b>Arcus<\/b> Other, Research Funding and Advisory Board\/Consulting. <br><b>Bayer<\/b> Other, Research Funding and Advisory Board\/Consulting. <br><b>Bristol-Myers Squibb<\/b> Other, Research Funding and Advisory Board\/Consulting. <br><b>Cycle for Survival<\/b> Other, Research Funding. <br><b>Department of Defense<\/b> Other, Research Funding and Advisory Board\/Consulting. <br><b>Eli Lilly<\/b> Other, Research Funding and Advisory Board\/Consulting. <br><b>Fred’s Team<\/b> Other, Research Funding. <br><b>Genentech\/Roche<\/b> Other, Research Funding. <br><b>Inspirna<\/b> Other, Research Funding and Advisory Board\/Consulting. <br><b>Merck<\/b> Other, Research Funding and Advisory Board\/Consulting. <br><b>NCI<\/b> Other, Research Funding. <br><b>Transcenta<\/b> Other, Research Funding. <br><b>Abbvie<\/b> Other, Advisory Boards\/Consulting. <br><b>Amerisource Bergen<\/b> Other, Advisory Boards\/Consulting. <br><b>Advisory Boards\/Consulting<\/b> Other, Advisory Boards\/Consulting. <br><b>Astellas<\/b> Other, Advisory Boards\/Consulting. <br><b>Basilea Pharmaceutica<\/b> Other, Advisory Boards\/Consulting. <br><b>Clinical Care Options<\/b> Other, Advisory Boards\/Consulting. <br><b>Daiichi-Sankyo<\/b> Other, Advisory Boards\/Consulting. <br><b>A. Tolcher, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract. <br><b>R. Mehta, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract. <br><b>M. Cecchini, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract. <br><b>Daiichi Sankyo<\/b> Other, Advisory Board Honoraria. <br><b>Regeneron<\/b> Advisory Board Honoraria. <br><b>Astra Zeneca<\/b> Other, Advisory Board Honoraria. <br><b>Parthenon Therapeutics<\/b> Other, Advisory Board Honoraria. <br><b>Incendia Therapeutics<\/b> Advisory Board Honoraria. <br><b>Bayer<\/b> Other, Advisory Board Honoraria. <br><b>Seattle Genetics<\/b> Other, Advisory Board Honoraria. <br><b>Taiho<\/b> Other, Advisory Board Honoraria. <br><b>B. Van Tine, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract. <br><b>M. Kundranda, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract. <br><b>Bayer<\/b> Other, COnsulting. <br><b>BPG Bio<\/b> Other, COnsulting. <br><b>Astra Zeneca<\/b> Other, Consulting. <br><b>Exact Sciences<\/b> Other, COnsulting. <br><b>Steris<\/b> Other, Consulting. <br><b>BMS<\/b> Other, COnsulting. <br><b>A. Olatunji, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract. <br><b>Taiho<\/b> Other, Consulting. <br><b>Pfizer<\/b> Other, Consulting. <br><b>QED Therapeutics<\/b> Other, Consulting. <br><b>Seagen<\/b> Other, Consulting. <br><b>BMS<\/b> Other, Consulting. <br><b>Aadi Bioscience<\/b> Other, Consulting. <br><b>M. R. Patel, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract. <br><b>ION harma<\/b> Other. <br><b>Janssen Oncology<\/b> Other, Honoraria. <br><b>Olema Pharmaceuticals<\/b> Other, Consulting. <br><b>Daiichi Sankyo\/UCB Japan<\/b> Other, Consulting. <br><b>Accutar Biotech<\/b> Other, Consulting. <br><b>Acerta Therapeutics<\/b> Grant\/Contract, Institutional Research Funding. <br><b>ADC Therapeutics<\/b> Grant\/Contract, Institutional Research Funding. <br><b>Agenus<\/b> Grant\/Contract, Institutional Research Funding. <br><b>Aileron<\/b> Grant\/Contract, Institutional Research Funding. <br><b>AstraZeneca<\/b> Grant\/Contract, Institutional Research Funding. <br><b>AstraZeneca<\/b> Grant\/Contract, Institutional Research Funding. <br><b>BioNTech AG<\/b> Grant\/Contract, Institutional Research Funding. <br><b>Boehringer Ingelheim<\/b> Institutional Research Funding. <br><b>Celgene<\/b> Grant\/Contract, Institutional Research Funding. <br><b>CicloMed<\/b> Grant\/Contract, Institutional Research Funding. <br><b>Clovis Oncology<\/b> Grant\/Contract, Institutional Research Funding. <br><b>Daiichi Sankyo<\/b> Grant\/Contract, Institutional Research Funding. <br><b>Lilly<\/b> Grant\/Contract, Institutional Research Funding. <br><b>Gilead Sciences<\/b> Grant\/Contract, Institutional Research Funding. <br><b>J. Berlin, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract.<br><b>C. Rocha-Lima, <\/b> None.&nbsp;<br><b>D. Monga, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract. <br><b>Revolution Medicine<\/b> Other, Consulting. <br><b>BMS<\/b> Other, Honoraria. <br><b>Fog Pharma<\/b> Other, COnsulting. <br><b>Astra Zeneca<\/b> Other, Speaker’s Bureau. <br><b>Bristol Myers Squibb<\/b> Other, Speaker’s Bureau. <br><b>Revolution<\/b> Other, Advisory Board\/Consulting. <br><b>Aligos<\/b> Other, Advisory Board\/Consulting. <br><b>Surrozen<\/b> Other, Advisory Board\/Consulting. <br><b>B. George, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract. <br><b>IPSEN<\/b> Other, Consulting. <br><b>BMS<\/b> Other, Consulting. <br><b>Foundation Medicine<\/b> Other, Consulting. <br><b>Roche\/Genentech<\/b> Other, Consulting. <br><b>Pfizer<\/b> Other, Consulting. <br><b>Taiho<\/b> Other, Consulting. <br><b>A. Scott, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Grant\/Contract. <br><b>Z. Xia, <\/b> <br><b>Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, Jiangsu, P. R. China<\/b> Employment. <br><b>M. Elsafy, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Employment. <br><b>E. Jones, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Employment. <br><b>Z. Yao, <\/b> <br><b>Transcenta Therapeutics Inc., Princeton NJ, USA<\/b> Employment. <br><b>C. Qi, <\/b> <br><b>Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, Jiangsu, P. R. China<\/b> Employment. <br><b>C. Germa, <\/b> <br><b>Transcenta Therapeutics Inc.<\/b> Employment.<br><b>N. Gabrail, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11499","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT132","PresenterBiography":null,"PresenterDisplayName":"Yelena Janjigian, MD","PresenterKey":"c98b2943-e42e-4628-bb3d-93f629d6e34d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT132. A Phase I\/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A Phase I\/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Anti-PD-1,Immuno-oncology,Cholangiocarcinoma,T cell,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>F. Ghiringhelli<\/b><sup>1<\/sup>, R. Kim<sup>2<\/sup>, T. Macarulla<sup>3<\/sup>, I. Moreno<sup>4<\/sup>, A. Razak<sup>5<\/sup>, J. Rodon<sup>6<\/sup>, C.-Y. Liao<sup>7<\/sup>, T. Marron<sup>8<\/sup>, J. Raimbourg<sup>9<\/sup>, H. Kaplon<sup>10<\/sup>, J. Geromini<sup>10<\/sup>, N. Harouki<sup>10<\/sup>, C. Rodrigues<sup>10<\/sup>, P. Darcel<sup>10<\/sup>, N. Jorgen Skartved<sup>11<\/sup>, R. Hald<sup>11<\/sup>, D. Lopez-Ravnborg<sup>11<\/sup>, P. He<sup>12<\/sup>, X. Ianopoulos<sup>12<\/sup>, V. Askoxylakis<sup>12<\/sup>, N. J. Lakhani<sup>13<\/sup>, S. Davis<sup>14<\/sup>, A. Mahipal<sup>15<\/sup>; <br\/><sup>1<\/sup>Centre Georges-Francois Leclerc, Dijon, France, <sup>2<\/sup>Moffit Cancer Center, Tampa, FL, <sup>3<\/sup>Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, <sup>4<\/sup>Centro Integral Oncologico Clara Campal, Madrid, Spain, <sup>5<\/sup>Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>6<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>7<\/sup>University of Chicago, Chicago, IL, <sup>8<\/sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>9<\/sup>Institut de Cancerologie de l'Ouest, Saint Herblain, France, <sup>10<\/sup>Servier, Gif-sur-Yvette, France, <sup>11<\/sup>Servier, Ballerup, Denmark, <sup>12<\/sup>Servier, Boston, MA, <sup>13<\/sup>START Midwest, Grand Rapids, MI, <sup>14<\/sup>University of Colorado, Aurora, CO, <sup>15<\/sup>Mayo Clinic - Rochester, Rochester, MN","CSlideId":"","ControlKey":"bd268d0e-8e6c-4876-865b-37a6163579df","ControlNumber":"10829","DisclosureBlock":"&nbsp;<b>F. Ghiringhelli, <\/b> None.&nbsp;<br><b>R. Kim, <\/b> <br><b>AstraZeneca; Exelixis; Ipsen; Eisai; Roche<\/b> Other, Honorarium. <br><b>Pfizer<\/b> Other, consulting\/advisory role. <br><b>Incyte; AstraZeneca<\/b> Other, speaker’s bureau.<br><b>T. Macarulla, <\/b> None..<br><b>I. Moreno, <\/b> None.&nbsp;<br><b>A. Razak, <\/b> <br><b>Adaptimmune; Bayer; GlaxoSmithKline; Inhibrx; Medison<\/b> Other, Consulting or Advisory Role. <br><b>23 and Me; Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; Frontier Therapeutics; GlaxoSmithKline; Iterion Therapeutics<\/b> Other, Research Funding. <br><b>Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche\/Genentech; Symphogen<\/b> Other, Research Funding. <br><b>Medison<\/b> Other, Expert Testimony.<br><b>J. Rodon, <\/b> None..<br><b>C. Liao, <\/b> None..<br><b>T. Marron, <\/b> None..<br><b>J. Raimbourg, <\/b> None.&nbsp;<br><b>H. Kaplon, <\/b> <br><b>Servier<\/b> Employment. <br><b>J. Geromini, <\/b> <br><b>Servier<\/b> Employment. <br><b>N. Harouki, <\/b> <br><b>Servier<\/b> Employment. <br><b>C. Rodrigues, <\/b> <br><b>Servier<\/b> Employment. <br><b>P. Darcel, <\/b> <br><b>Servier<\/b> Employment. <br><b>N. Jorgen Skartved, <\/b> <br><b>Servier<\/b> Employment. <br><b>R. Hald, <\/b> <br><b>Servier<\/b> Employment. <br><b>D. Lopez-Ravnborg, <\/b> <br><b>Servier<\/b> Employment. <br><b>P. He, <\/b> <br><b>Servier<\/b> Employment. <br><b>X. Ianopoulos, <\/b> <br><b>Servier<\/b> Employment. <br><b>V. Askoxylakis, <\/b> <br><b>Servier<\/b> Employment.<br><b>N. J. Lakhani, <\/b> None.&nbsp;<br><b>S. Davis, <\/b> <br><b>Merck<\/b> Grant\/Contract. <br><b>BMS<\/b> Grant\/Contract. <br><b>I-Mab<\/b> Grant\/Contract. <br><b>TriSalus Life Sciences<\/b> Grant\/Contract. <br><b>Tvardi Therapeutics<\/b> Grant\/Contract. <br><b>EMD Serono<\/b> Grant\/Contract. <br><b>Oric Pharmaceutical<\/b> Grant\/Contract. <br><b>A. Mahipal, <\/b> <br><b>AstraZeneca\/MedImmune<\/b> Other, Consulting or Advisory Role. <br><b>QED Therapeutics<\/b> Other, Consulting or Advisory Role. <br><b>Taiho Oncology<\/b> Other, Consulting or Advisory Role. <br><b>AstraZeneca<\/b> Other, Speakers' Bureau. <br><b>Taiho Pharmaceutical<\/b> Other, Research Funding.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11500","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT133","PresenterBiography":null,"PresenterDisplayName":"Fanny Cazade","PresenterKey":"c56012f2-dce0-4eb2-8083-15adc3b25d45","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT133. A phase 1b multicenter study of anti-TIM3 (S095018\/Sym023) in combination with anti-PD1 (Sym021) in patients with advanced\/metastatic recurrent biliary tract cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1b multicenter study of anti-TIM3 (S095018\/Sym023) in combination with anti-PD1 (Sym021) in patients with advanced\/metastatic recurrent biliary tract cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Interleukin-6,PD-1,Therapeutics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>O. B. Alese<\/b><sup>1<\/sup>, O. Gbolahan<sup>1<\/sup>, K. M. Coleman<sup>1<\/sup>, Y. Cao<sup>1<\/sup>, S. Kane<sup>1<\/sup>, S. Craven<sup>1<\/sup>, E. Greene<sup>1<\/sup>, N. Horvat<sup>1<\/sup>, A. McDonald<sup>1<\/sup>, W. L. Shaib<sup>2<\/sup>, C. S. Wu<sup>3<\/sup>, M. Akce<sup>4<\/sup>, M. Diab<sup>5<\/sup>, J. M. Switchenko<sup>1<\/sup>, G. B. Lesinski<sup>1<\/sup>, B. F. El-Rayes<sup>4<\/sup>; <br\/><sup>1<\/sup>Winship Cancer Institute of Emory University, Atlanta, GA, <sup>2<\/sup>Northwest Georgia Oncology Center, Atlanta, GA, <sup>3<\/sup>Mayo Clinic, Phoenix, AZ, <sup>4<\/sup>University of Alabama, Birmingham, AL, <sup>5<\/sup>Henry Ford Health, Detroit, MI","CSlideId":"","ControlKey":"7711514d-a69a-423b-94a4-0079c5ca3edb","ControlNumber":"9758","DisclosureBlock":"<b>&nbsp;O. B. Alese, <\/b> <br><b>Ipsen Pharmaceuticals<\/b> Other, Advisory Board. <br><b>Aadi Bioscience<\/b> Other, Advisory Board. <br><b>Taiho<\/b> Other, Advisory Board. <br><b>Pfizer<\/b> Other, Advisory Board. <br><b>Takeda&#8194;<\/b> Other, Advisory Board. <br><b>Exelixis<\/b> Other, Advisory Board. <br><b>AstraZeneca<\/b> Other, Advisory Board. <br><b>Bristol Myers Squibb<\/b> Other, Advisory Board. <br><b>Seagen Inc<\/b> Other, Advisory Board.<br><b>O. Gbolahan, <\/b> None..<br><b>K. M. Coleman, <\/b> None..<br><b>Y. Cao, <\/b> None..<br><b>S. Kane, <\/b> None..<br><b>S. Craven, <\/b> None..<br><b>E. Greene, <\/b> None..<br><b>N. Horvat, <\/b> None..<br><b>A. McDonald, <\/b> None..<br><b>W. L. Shaib, <\/b> None..<br><b>C. S. Wu, <\/b> None..<br><b>M. Akce, <\/b> None..<br><b>M. Diab, <\/b> None..<br><b>J. M. Switchenko, <\/b> None..<br><b>G. B. Lesinski, <\/b> None..<br><b>B. F. El-Rayes, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11503","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT136","PresenterBiography":null,"PresenterDisplayName":"Olatunji Alese, MD","PresenterKey":"5f9f89dd-e1e6-44a3-8a1d-ece97a1e1feb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT136. Phase Ib study of siltuximab and spartalizumab in advanced pancreatic cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase Ib study of siltuximab and spartalizumab in advanced pancreatic cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Prostate cancer,Androgen deprivation therapy,Regulatory T cells,CTLA-4,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>P. J. McCann<\/b><sup>1<\/sup>, C. R. Ager<sup>2<\/sup>, A. Z. Obradovic<sup>1<\/sup>, M. G. Chaimowitz<sup>3<\/sup>, S. Pan<sup>4<\/sup>, C. J. Laplaca<sup>5<\/sup>, P. Shah<sup>4<\/sup>, R. K. Virk<sup>6<\/sup>, C. B. Anderson<sup>5<\/sup>, C. S. Spina<sup>1<\/sup>, K. D. Runcie<sup>7<\/sup>, M. N. Stein<sup>7<\/sup>, C. G. Drake<sup>7<\/sup>, M. C. Dallos<sup>8<\/sup>; <br\/><sup>1<\/sup>Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, <sup>2<\/sup>Mayo Clinic Arizona, Department of Urology, Scottsdale, AZ, <sup>3<\/sup>Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY, <sup>4<\/sup>Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, <sup>5<\/sup>Department of Urology, Columbia University Irving Medical Center, New York, NY, <sup>6<\/sup>Department of Pathology, Columbia University Irving Medical Center, New York, NY, <sup>7<\/sup>Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, <sup>8<\/sup>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","CSlideId":"","ControlKey":"bdaed774-f6de-405b-a7f8-fdd1101d4e5a","ControlNumber":"9877","DisclosureBlock":"&nbsp;<b>P. J. McCann, <\/b> None..<br><b>C. R. Ager, <\/b> None..<br><b>A. Z. Obradovic, <\/b> None..<br><b>M. G. Chaimowitz, <\/b> None..<br><b>S. Pan, <\/b> None..<br><b>C. J. Laplaca, <\/b> None..<br><b>P. Shah, <\/b> None..<br><b>R. K. Virk, <\/b> None..<br><b>C. B. Anderson, <\/b> None..<br><b>C. S. Spina, <\/b> None..<br><b>K. D. Runcie, <\/b> None.&nbsp;<br><b>M. N. Stein, <\/b> <br><b>Exelis, Merck Sharpe and Dohme, and Xencor<\/b> Other, Consultant. <br><b>C. G. Drake, <\/b> <br><b>Johnson & Johnson<\/b> Employment. <br><b>Johns Hopkins University to BMS; Janssen<\/b> Patent. <br><b>AZ Medimmune; BMS; Pfizer; Roche; Sanofi Aventis; Genentech; Merck; Janssen<\/b> Other, Prior paid consultant. <br><b>M. C. Dallos, <\/b> <br><b>Bayer; Bristol-Myers Squibb; Sanofi.<\/b> Other, Consultant.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11504","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT137","PresenterBiography":null,"PresenterDisplayName":"Patrick McCann, BS","PresenterKey":"b2d2ac39-ba26-41ce-93ed-b2d55847c204","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT137. Efficacy and immunological outcomes of non-fucosylated anti-CTLA-4 (BMS-986218) + degarelix acetate vs. degarelix acetate alone in men with high-risk localized prostate cancer (Neo-Red-P)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Efficacy and immunological outcomes of non-fucosylated anti-CTLA-4 (BMS-986218) + degarelix acetate vs. degarelix acetate alone in men with high-risk localized prostate cancer (Neo-Red-P)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Prostate cancer,Ipilimumab,Nivolumab,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. M. Tsimberidou<\/b><sup>1<\/sup>, A. Drakaki<sup>2<\/sup>, D. N. Khalil<sup>3<\/sup>, K. Okrah<sup>4<\/sup>, M. Schachter<sup>4<\/sup>, S. Gautam<sup>5<\/sup>, D. M. Da Silva<sup>4<\/sup>, F. A. Alayli<sup>4<\/sup>, C. N. Spencer<sup>4<\/sup>, W. Foo<sup>1<\/sup>, M. Adamow<sup>3<\/sup>, P. Wong<sup>3<\/sup>, J. Fairchild<sup>4<\/sup>, J. Arnott<sup>4<\/sup>, U. Dugan<sup>4<\/sup>, S. Boffo<sup>6<\/sup>, L. Salvador<sup>6<\/sup>, C. R. Cabanski<sup>4<\/sup>, S. K. Subudhi<sup>1<\/sup>, P. Sharma<sup>1<\/sup>; <br\/><sup>1<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>University of California, Los Angeles, Los Angeles, CA, <sup>3<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>4<\/sup>Parker Institute for Cancer Immunotherapy, San Francisco, CA, <sup>5<\/sup>LumaBridge, San Antonio, TX, <sup>6<\/sup>Bristol Myers Squibb, Princeton, NJ","CSlideId":"","ControlKey":"209ed565-1150-44d1-a14b-827f88abd254","ControlNumber":"10476","DisclosureBlock":"<b>&nbsp;A. M. Tsimberidou, <\/b> <br><b>OBI Pharma USA, Inc.<\/b> Grant\/Contract. <br><b>Agenus<\/b> Grant\/Contract. <br><b>Tachyon Therapeutics<\/b> Grant\/Contract. <br><b>Tempus<\/b> Grant\/Contract. <br><b>Tvardi Therapeutics<\/b> Grant\/Contract. <br><b>Immatics<\/b> Grant\/Contract. <br><b>Novocure<\/b> Grant\/Contract. <br><b>Orionis Biosciences<\/b> Grant\/Contract. <br><b>Vincerx Pharma<\/b> Grant\/Contract. <br><b>Diaccurate<\/b> Grant\/Contract. <br><b>NEX-I<\/b> Grant\/Contract. <br><b>BrYet<\/b> Grant\/Contract. <br><b>MacroGenics<\/b> Grant\/Contract. <br><b>BioEclipse Therapeutics<\/b> Grant\/Contract. <br><b>Avstera Therapeutics<\/b> Grant\/Contract.<br><b>A. Drakaki, <\/b> None.&nbsp;<br><b>D. N. Khalil, <\/b> <br><b>AbbVie<\/b> Grant\/Contract. <br><b>Akamis Bio<\/b> Grant\/Contract. <br><b>PrimeFour Therapeutics<\/b> Grant\/Contract.<br><b>K. Okrah, <\/b> None..<br><b>M. Schachter, <\/b> None..<br><b>S. Gautam, <\/b> None.&nbsp;<br><b>D. M. Da Silva, <\/b> <br><b>Sanofi US<\/b> Employment.<br><b>F. A. Alayli, <\/b> None..<br><b>C. N. Spencer, <\/b> None..<br><b>W. Foo, <\/b> None..<br><b>M. Adamow, <\/b> None..<br><b>P. Wong, <\/b> None..<br><b>J. Fairchild, <\/b> None..<br><b>J. Arnott, <\/b> None.&nbsp;<br><b>U. Dugan, <\/b> <br><b>Bristol Myers Squibb<\/b> Stock. <br><b>S. Boffo, <\/b> <br><b>Bristol Myers Squibb<\/b> Employment. <br><b>L. Salvador, <\/b> <br><b>Bristol Myers Squibb<\/b> Employment.<br><b>C. R. Cabanski, <\/b> None..<br><b>S. K. Subudhi, <\/b> None.&nbsp;<br><b>P. Sharma, <\/b> <br><b>Achelois; Adaptive Biotechnologies; Affini-T; Apricity; BioAtla; BioNTech; Candel Therapeutics; Catalio; Codiak; Constellation; Dragonfly; Earli; Enable Medicine; Glympse; Hummingbird; ImaginAb<\/b> Grant\/Contract. <br><b>Infinity Pharma; Jounce; JSL Health; Lava Therapeutics; Lytix; Marker; MedImmune; Oncolytics; PBM Capital; Phenomic AI; Polaris Pharma; Sporos; Time Bioventures; Trained Therapeutix; Venn Biosciences<\/b> Grant\/Contract.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11505","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT138","PresenterBiography":null,"PresenterDisplayName":"Apostolia Tsimberidou, MD;PhD","PresenterKey":"b3608c07-755c-404b-91a2-383b742f8dc2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT138. Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Ovarian cancer,Pembrolizumab,Oncolytic adenovirus,Immunomodulation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. H. A. Clubb<\/b><sup>1<\/sup>, M. S. Block<sup>2<\/sup>, J. Mäenpää<sup>3<\/sup>, S. Pakola<sup>4<\/sup>, L. Haybout<sup>1<\/sup>, D. C. A. Quixabeira<sup>1<\/sup>, T. Kudling<sup>4<\/sup>, M. van der Heijden<sup>4<\/sup>, E. Jirovec<sup>1<\/sup>, T. Alanko<sup>3<\/sup>, D. A. Adamo<sup>5<\/sup>, S. Ramadan<sup>3<\/sup>, J. Sormunen<sup>3<\/sup>, J. Kononen<sup>3<\/sup>, J. W. Cohen<sup>6<\/sup>, N. Singh<sup>7<\/sup>, J. Goldfinch<sup>1<\/sup>, S. Sorsa<sup>1<\/sup>, R. Havunen<sup>1<\/sup>, C. Kistler<sup>1<\/sup>, J. M. Santos<sup>1<\/sup>, V. Cervera-Carrascon<sup>1<\/sup>, A. Hemminki<sup>1<\/sup>; <br\/><sup>1<\/sup>TILT Biotherapeutics, Helsinki, Finland, <sup>2<\/sup>Mayo Clinic Cancer Center, Rochester, MN, <sup>3<\/sup>Docrates Cancer Center, Helsinki, Finland, <sup>4<\/sup>University of Helsinki, Helsinki, Finland, <sup>5<\/sup>Mayo Clinic, Rochester, MN, <sup>6<\/sup>Merck Research Labs, Rahway, NJ, <sup>7<\/sup>Merck, Rahway, NJ","CSlideId":"","ControlKey":"1c6b3602-9841-4b79-a04e-f26830736e24","ControlNumber":"9869","DisclosureBlock":"<b>&nbsp;J. H. A. Clubb, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment, Stock, Stock Option.<br><b>M. S. Block, <\/b> None..<br><b>J. Mäenpää, <\/b> None..<br><b>S. Pakola, <\/b> None.&nbsp;<br><b>L. Haybout, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment. <br><b>D. C. A. Quixabeira, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment.<br><b>T. Kudling, <\/b> None..<br><b>M. van der Heijden, <\/b> None.&nbsp;<br><b>E. Jirovec, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment.<br><b>T. Alanko, <\/b> None..<br><b>D. A. Adamo, <\/b> None..<br><b>S. Ramadan, <\/b> None..<br><b>J. Sormunen, <\/b> None..<br><b>J. Kononen, <\/b> None.&nbsp;<br><b>J. W. Cohen, <\/b> <br><b>Merck<\/b> Employment. <br><b>N. Singh, <\/b> <br><b>Merck<\/b> Employment. <br><b>J. Goldfinch, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment. <br><b>S. Sorsa, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment. <br><b>R. Havunen, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment. <br><b>C. Kistler, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment, Stock, Stock Option. <br><b>J. M. Santos, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment, Stock, Stock Option. <br><b>V. Cervera-Carrascon, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment, Stock, Stock Option. <br><b>A. Hemminki, <\/b> <br><b>TILT Biotherapeutics<\/b> Employment, Stock, Stock Option, Patent, Founder and CEO.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11506","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT139","PresenterBiography":null,"PresenterDisplayName":"James Clubb, MS","PresenterKey":"59d7f68b-4bcd-45ce-be11-281e5a2164ce","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT139. Immunological activity of oncolytic adenovirus encoding TNF&#945; and IL-2 (TILT-123) in combination with pembrolizumab in platinum resistant or refractory ovarian cancer patients","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Immunological activity of oncolytic adenovirus encoding TNF&#945; and IL-2 (TILT-123) in combination with pembrolizumab in platinum resistant or refractory ovarian cancer patients","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Head and neck squamous cell carcinoma,Drug-drug interaction,xevinapant,food effect,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>V. Nicolas-Métral<\/b><sup>1<\/sup>, E. Rouits<sup>1<\/sup>, C. Riff<sup>1<\/sup>, D. Spaggiari<sup>1<\/sup>, N. Wiedemann<sup>1<\/sup>, P. Colin<sup>1<\/sup>, E. Harrison-Moench<sup>2<\/sup>, R. Crabbé<sup>1<\/sup>, H. Nauwelaerts<sup>1<\/sup>, A. Schroeder<sup>2<\/sup>, C. Haefliger<sup>1<\/sup>, Y. Vugmeyster<sup>3<\/sup>; <br\/><sup>1<\/sup>Debiopharm International SA, Lausanne, Switzerland, <sup>2<\/sup>the healthcare business of Merck KGaA, Darmstadt, Germany, <sup>3<\/sup>EMD Serono, Billerica, MA","CSlideId":"","ControlKey":"d10ab346-b7f5-42f1-9bc5-ad929b461e10","ControlNumber":"9934","DisclosureBlock":"<b>&nbsp;V. Nicolas-Métral, <\/b> <br><b>Debiopharm International SA<\/b> Employment. <br><b>E. Rouits, <\/b> <br><b>Pharmalex<\/b> Employment. <br><b>Debiopharm International SA<\/b> Other, Debiopharm employee during study work period. <br><b>C. Riff, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>Debiopharm International SA<\/b> Other, Debiopharm employee during study work period. <br><b>D. Spaggiari, <\/b> <br><b>Debiopharm International SA<\/b> Employment. <br><b>N. Wiedemann, <\/b> <br><b>Debiopharm International SA<\/b> Employment. <br><b>P. Colin, <\/b> <br><b>BMS<\/b> Employment. <br><b>Debiopharm International SA<\/b> Other, Debiopharm employee during study work period. <br><b>E. Harrison-Moench, <\/b> <br><b>the healthcare business of Merck KGaA<\/b> Employment. <br><b>R. Crabbé, <\/b> <br><b>Debiopharm International SA<\/b> Employment. <br><b>H. Nauwelaerts, <\/b> <br><b>Debiopharm International SA<\/b> Employment. <br><b>A. Schroeder, <\/b> <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>C. Haefliger, <\/b> <br><b>Debiopharm International SA<\/b> Employment. <br><b>Y. Vugmeyster, <\/b> <br><b>EMD Serono<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11507","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT140","PresenterBiography":null,"PresenterDisplayName":"Valerie Nicolas-Metral, PhD","PresenterKey":"875f6e6b-0136-4f3f-9d49-bec0e6bbf01b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT140. A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a proton pump inhibitor in healthy volunteers","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a proton pump inhibitor in healthy volunteers","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Immunotherapy,Head and neck squamous cell carcinoma,Clinical outcomes,Immunogenicity,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. E. Bauman<\/b><sup>1<\/sup>, R. A. Julian<sup>2<\/sup>, J. L. Geiger<sup>3<\/sup>, J. M. Mehnert<sup>4<\/sup>, J. M. Clarke<sup>5<\/sup>, M. R. Patel<sup>6<\/sup>, M. Gutierrez<sup>7<\/sup>, J. F. Gainor<sup>8<\/sup>, S. Srivats<sup>9<\/sup>, Z. Zhang<sup>9<\/sup>, A. Rao<sup>9<\/sup>, V. Sehgal<sup>9<\/sup>, P. Hou<sup>9<\/sup>, M. Morrissey<sup>9<\/sup>, I. Feldman<sup>9<\/sup>, L. Srinivasan<sup>9<\/sup>, P. Aanur<sup>9<\/sup>, M. Brown<sup>9<\/sup>, R. S. Meehan<sup>9<\/sup>; <br\/><sup>1<\/sup>George Washington University, Washington, DC, <sup>2<\/sup>University of Arizona Cancer Center, Tucson, AZ, <sup>3<\/sup>The Cleveland Clinic Foundation, Cleveland, OH, <sup>4<\/sup>Perlmutter Cancer Center at NYU Langone Health, New York, NY, <sup>5<\/sup>Duke University Medical Center, Durham, NC, <sup>6<\/sup>Florida Cancer Specialists, Sarasota, FL, <sup>7<\/sup>Hackensack University Medical Center, Hackensack, NJ, <sup>8<\/sup>Massachusetts General Hospital, Boston, MA, <sup>9<\/sup>Moderna Inc, Cambridge, MA","CSlideId":"","ControlKey":"aff00e68-cbb3-4aec-bd84-72afaec54e76","ControlNumber":"10282","DisclosureBlock":"&nbsp;<b>J. E. Bauman, <\/b> None.&nbsp;<br><b>R. A. Julian, <\/b> <br><b>Jazz Pharmaceuticals<\/b> Other, advisory board; speaker fees. <br><b>BioAtla<\/b> Other, advisory board. <br><b>Bristol Myers Squibb<\/b> Other, advisory board. <br><b>Merck<\/b> Other, advisory board. <br><b>Best of ASCO speaker<\/b> Travel. <br><b>APPOS Conference Speaker<\/b> Travel. <br><b>NCI Clinical Trial Planning Meeting<\/b> Other, Unpaid leadership role. <br><b>J. L. Geiger, <\/b> <br><b>Merck<\/b> Other, consulting fees. <br><b>EMD Serono<\/b> Other, consulting fees. <br><b>Astellas<\/b> Other, consulting fees, honoraria. <br><b>Aveo Oncology<\/b> Other, honoraria. <br><b>J. M. Mehnert, <\/b> <br><b>Regeneron<\/b> Other, consulting fees. <br><b>Merck<\/b> Other, consulting fees. <br><b>Bristol Myers Squibb<\/b> Other, consulting fees. <br><b>Novartis<\/b> Other, consulting fees. <br><b>SeaGen<\/b> Other, consulting fees. <br><b>Moderna<\/b> Other, advisory board. <br><b>J. M. Clarke, <\/b> <br><b>Bristol Myers Squibb, Genentech, Spectrum, Adaptimmune, AbbVie, Moderna, GlaxoSmithKline, Array, AstraZeneca, Grid Therapeutics, CBMG, Pfizer<\/b> Grant\/Contract. <br><b>AstraZeneca , Merck , Pfizer, Spectrum, Genentech, Novartis , Turning Point, G1 Therapeutics, Vivacitas, Omega, Amgen, Corbus, Sanofi<\/b> Other, consulting fees. <br><b>G1 Therapeutics, STCube<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board. <br><b>Board of Directors: Lung Cancer Initiative of North Carolina<\/b> Other, leadership role (uncompensated). <br><b>M. R. Patel, <\/b> <br><b>Moderna<\/b> Grant\/Contract. <br><b>Janssen<\/b> Other, consulting fees. <br><b>EMD Serono<\/b> Other, consulting fees. <br><b>Pfizer<\/b> Other, consulting fees. <br><b>Accutar<\/b> Other, consulting fees. <br><b>M. Gutierrez, <\/b> <br><b>Guardant<\/b> Other, consulting fees. <br><b>Cellularity<\/b> Other, consulting fees. <br><b>Merck<\/b> Other, consulting fees. <br><b>Sanofi<\/b> Other, advisory board. <br><b>J. F. Gainor, <\/b> <br><b>Amgen, AstraZeneca, Mariana Therapeutics, Mirati Therapeutics, Merus Pharmaceuticals, Nuvalent, Pfizer, Novocure, AI Proteins, Novartis, Silverback Therapeutics, Sanofi, Blueprint Medicines, Bristol<\/b> Other, consulting fees. <br><b>Novartis, Merck, Novartis, Pfizer, Takeda<\/b> Other, honoraria. <br><b>Adaptimmune, Alexo, AstraZeneca, Blueprint, Bristol Myers Squibb, Genentech, Jounce, Merck, Moderna, Novartis, NextPoint, Palleon, Takeda<\/b> Grant\/Contract. <br><b>AI Proteins<\/b> Stock. <br><b>S. Srivats, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option. <br><b>Z. Zhang, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option. <br><b>A. Rao, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option, Travel. <br><b>V. Sehgal, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option. <br><b>AbbVie<\/b> Stock, Stock Option. <br><b>P. Hou, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option. <br><b>M. Morrissey, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option, Travel. <br><b>I. Feldman, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option. <br><b>L. Srinivasan, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option. <br><b>P. Aanur, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option. <br><b>M. Brown, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option. <br><b>Novartis<\/b> Stock, Stock Option. <br><b>Bristol Myers Squibb<\/b> Stock, Stock Option. <br><b>R. S. Meehan, <\/b> <br><b>Moderna<\/b> Employment, Stock, Stock Option.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11508","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT141","PresenterBiography":null,"PresenterDisplayName":"Julie Bauman, MD, MPH","PresenterKey":"1df46ef3-3385-4a67-b28f-04702bbd3d3e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT141. mRNA-4157 (V940) individualized neoantigen therapy (INT) + pembrolizumab (pembro) in advanced unresectable HPV- head &#38; neck carcinoma (HNSCC): Clinical &#38; translational analysis","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"mRNA-4157 (V940) individualized neoantigen therapy (INT) + pembrolizumab (pembro) in advanced unresectable HPV- head &#38; neck carcinoma (HNSCC): Clinical &#38; translational analysis","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL08-02 Molecular targeted therapy,,"},{"Key":"Keywords","Value":"BET inhibitors,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"M. Sun<sup>1<\/sup>, X. Jin<sup>2<\/sup>, <b>J. Guo<\/b><sup>2<\/sup>, X. Liu<sup>2<\/sup>, Y. Xu<sup>2<\/sup>, H. Lan<sup>2<\/sup>, J. Wang<sup>2<\/sup>, J. Zhen<sup>2<\/sup>, J. Yang<sup>2<\/sup>, L. Ding<sup>2<\/sup>, J. Qi<sup>1<\/sup>; <br\/><sup>1<\/sup>State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, <sup>2<\/sup>Betta Pharmaceuticals Co.,Ltd, Hangzhou, China","CSlideId":"","ControlKey":"3e72c2b5-73b7-4d76-a3ae-2751df44cacf","ControlNumber":"10588","DisclosureBlock":"&nbsp;<b>M. Sun, <\/b> None..<br><b>X. Jin, <\/b> None..<br><b>J. Guo, <\/b> None..<br><b>X. Liu, <\/b> None..<br><b>Y. Xu, <\/b> None..<br><b>H. Lan, <\/b> None..<br><b>J. Wang, <\/b> None..<br><b>J. Zhen, <\/b> None..<br><b>J. Yang, <\/b> None..<br><b>L. Ding, <\/b> None..<br><b>J. Qi, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11509","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT142","PresenterBiography":null,"PresenterDisplayName":"Jing Guo, PhD","PresenterKey":"6c04499e-33c9-4421-b629-f412d6ea74dd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT142. Phase 1 study of BPI-23314, a novel BET inhibitor and degrader, in advanced myeloid leukemia (AML)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1 study of BPI-23314, a novel BET inhibitor and degrader, in advanced myeloid leukemia (AML)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Immunotherapy,Interferons,Leukemias: acute myeloid,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Ito<\/b><sup>1<\/sup>, E. Geramita<sup>1<\/sup>, K. Ventura<sup>1<\/sup>, B. Neupane<sup>1<\/sup>, S. Bhise<sup>2<\/sup>, S. N. Furlan<sup>2<\/sup>, W. D. Shromchik<sup>1<\/sup>; <br\/><sup>1<\/sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>2<\/sup>University of Washington School of Medicine, Seattle, WA","CSlideId":"","ControlKey":"8962a31c-640d-4acc-8f23-cae17979f231","ControlNumber":"10794","DisclosureBlock":"<b>&nbsp;S. Ito, <\/b> <br><b>Horizon Therapeutics<\/b> Other, Drug supply for the clinical trial. <br><b>BlueSphere Bio<\/b> Grant\/Contract.<br><b>E. Geramita, <\/b> None..<br><b>K. Ventura, <\/b> None..<br><b>B. Neupane, <\/b> None..<br><b>S. Bhise, <\/b> None..<br><b>S. N. Furlan, <\/b> None.&nbsp;<br><b>W. D. Shromchik, <\/b> <br><b>BlueSphere Bio<\/b> Grant\/Contract, Patent.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11510","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT143","PresenterBiography":null,"PresenterDisplayName":"Sawa Ito, MD,PhD","PresenterKey":"0e6ef1a1-cbcc-4062-b382-ffe22df62bb8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT143. IFN-&#947; and donor leukocyte infusion to treat relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation&#8239;","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"IFN-&#947; and donor leukocyte infusion to treat relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation&#8239;","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Lymphoma,Lymphoma: Hodgkin's lymphoma,Small molecule inhibitor,Lymphoma: non-Hodgkin's lymphoma,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>P. Strati<\/b><sup>1<\/sup>, E. Gonzalez-Barca<sup>2<\/sup>, D. Morillo<sup>3<\/sup>, S. Ahmed<sup>1<\/sup>, D. Chraniuk<sup>4<\/sup>, S. Leppa<sup>5<\/sup>, F. de la Cruz Vicente<sup>6<\/sup>, P. Centkowski<sup>7<\/sup>, R. N. Pillai<sup>8<\/sup>, S. Nanda<sup>8<\/sup>, A. Khullar<sup>8<\/sup>, M. Hahka-Kemppinen<sup>8<\/sup>, V. Jayaprakash<sup>8<\/sup>, G. Gritti<sup>9<\/sup>; <br\/><sup>1<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, Spain, <sup>3<\/sup>Fundación Jiménez Díaz University Hospital, START Madrid-FJD Early Phase Unit, Madrid, Spain, <sup>4<\/sup>Nasz Lekarz Przychodnie Medyczne, Toru&#324;, Poland, <sup>5<\/sup>University of Helsinki and Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, Finland, <sup>6<\/sup>Hospital Universitario Virgen del Rocío, Sevilla, Spain, <sup>7<\/sup>KO-MED Centra Kliniczne Biala Podlaska, Podlaska, Poland, <sup>8<\/sup>HUTCHMED Intl, Florham Park, NJ, <sup>9<\/sup>Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy","CSlideId":"","ControlKey":"76a425f8-eec9-4785-997d-ed883affb0e3","ControlNumber":"10779","DisclosureBlock":"&nbsp;<b>P. Strati, <\/b> None..<br><b>E. Gonzalez-Barca, <\/b> None..<br><b>D. Morillo, <\/b> None..<br><b>S. Ahmed, <\/b> None..<br><b>D. Chraniuk, <\/b> None..<br><b>S. Leppa, <\/b> None..<br><b>F. de la Cruz Vicente, <\/b> None..<br><b>P. Centkowski, <\/b> None.&nbsp;<br><b>R. N. Pillai, <\/b> <br><b>HUTCHMED Intl<\/b> Employment. <br><b>S. Nanda, <\/b> <br><b>HUTCHMED Intl<\/b> Employment. <br><b>A. Khullar, <\/b> <br><b>HUTCHMED Intl<\/b> Employment. <br><b>M. Hahka-Kemppinen, <\/b> <br><b>HUTCHMED Intl<\/b> Employment. <br><b>V. Jayaprakash, <\/b> <br><b>HUTCHMED Intl<\/b> Employment.<br><b>G. Gritti, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11511","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT144","PresenterBiography":null,"PresenterDisplayName":"Vijayvel Jayaprakash, MBBS;PhD","PresenterKey":"93dec447-4b79-4f2c-bca3-d15afa30406c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT144. Safety and efficacy of HMPL-523 (Syk inhibitor) in patients with relapsed or refractory lymphoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Safety and efficacy of HMPL-523 (Syk inhibitor) in patients with relapsed or refractory lymphoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Mantle cell lymphoma,Efficacy,Toxicity,Combination therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. J. Pu<\/b><sup>1<\/sup>, K. Berger<sup>2<\/sup>, D. Claxton<sup>3<\/sup>, J. Drabick<sup>1<\/sup>, T. Loughran, Jr.<sup>4<\/sup>, E. Epner<sup>3<\/sup>; <br\/><sup>1<\/sup>VA Boston Healthcare System, Harvard Medical School, Boston, MA, <sup>2<\/sup>Weill Cornell Medical College, New York, NY, <sup>3<\/sup>Penn State Hershey Cancer Institute, Hershey, PA, <sup>4<\/sup>University of Viginia Cancer Center, Charlottesville, VA","CSlideId":"","ControlKey":"3dae9bcc-71c9-4d27-8672-76b702763a6e","ControlNumber":"10621","DisclosureBlock":"&nbsp;<b>J. J. Pu, <\/b> None..<br><b>K. Berger, <\/b> None..<br><b>D. Claxton, <\/b> None..<br><b>J. Drabick, <\/b> None..<br><b>T. Loughran, <\/b> None..<br><b>E. Epner, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11512","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT145","PresenterBiography":null,"PresenterDisplayName":"Jeffrey Pu, MD;PhD","PresenterKey":"a44c1fcb-63e2-4860-9529-df6e8bf0884e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT145. The final results of a phase I study using velcade (bortezomib), cladribine, and rituximab (VCR) in treating elderly patient with mantle cell lymphoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"The final results of a phase I study using velcade (bortezomib), cladribine, and rituximab (VCR) in treating elderly patient with mantle cell lymphoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Bcl-2 protein family,Bcl-xL,Non-Hodgkin's lymphoma,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>G. Chong<\/b><sup>1<\/sup>, F. Morschhauser<sup>2<\/sup>, A. Herrera<sup>3<\/sup>, K.-S. Eom<sup>4<\/sup>, T. Kim<sup>5<\/sup>, M. Wang<sup>6<\/sup>, C. Hall<sup>7<\/sup>, F. Cader<sup>8<\/sup>, K. Beyfuss<sup>9<\/sup>, P. Cheung<sup>10<\/sup>, W. Quan<sup>8<\/sup>, S. Sharma<sup>10<\/sup>, Y. Marmor<sup>10<\/sup>, J. Saeh<sup>11<\/sup>, J. Mariz<sup>12<\/sup>; <br\/><sup>1<\/sup>Olivia Newton-John Cancer Centre, Heidelberg, Australia, <sup>2<\/sup>Centre Hospitalier Universitaire de Lille, Lille, France, <sup>3<\/sup>City of Hope Medical Center, Duarte, CA, <sup>4<\/sup>The Catholic University of&#8239;Korea-Seoul St.&#8239;Mary's Hospital, Seoul, Korea, Republic of, <sup>5<\/sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>6<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>7<\/sup>Oncology R&D, AstraZeneca, Gaithersburg, MD, <sup>8<\/sup>Oncology R&D, AstraZeneca, Cambridge, United Kingdom, <sup>9<\/sup>Oncology R&D, AstraZeneca, Mississauga, ON, Canada, <sup>10<\/sup>Oncology R&D, AstraZeneca, South San Francisco, CA, <sup>11<\/sup>Oncology R&D, AstraZeneca, Waltham, MA, <sup>12<\/sup>Instituto Português Oncologia Francisco Gentil do Porto, Porto, Portugal","CSlideId":"","ControlKey":"cc54b9bf-0b40-4963-ac5a-05ec96f43686","ControlNumber":"10362","DisclosureBlock":"<b>&nbsp;G. Chong, <\/b> <br><b>Astra Zeneca<\/b> Other, Research\/funding. <br><b>Regeneron, Bristol Myers Squibb, Bayer, Merck, Isofol, Pharmacyclics, HutchMed, Incyte, Morphosys, Amgen, Dizal<\/b> Other, Research\/funding. <br><b>Takeda, Bristol Myers Squibb<\/b> Other, Ad Board. <br><b>F. Morschhauser, <\/b> <br><b>Roche, Gilead Sciences, Novartis, AbbVie, Genmab, BMS<\/b> Other, Consulting fees. <br><b>Chugai, Takeda, Roche<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Roche, AstraZeneca, AbbVie<\/b> Other, Ad Board. <br><b>A. Herrera, <\/b> <br><b>Bristol Myers Squibb, Genentech, Merck, Seattle Genetics, AstraZeneca, ADC Therapeutics<\/b> Other, Research, funding, consultancy. <br><b>KiTE Pharma, Gilead Sciences,<\/b> Other, Research and funding. <br><b>Karyopharm, Takeda, Tubulis, Regeneron, Genmab, Pfizer, Caribou Biosciences, Adicet Bio, AbbVie, Allogene Therapeutics<\/b> Other, Consultancy. <br><b>K. Eom, <\/b> <br><b>Ubix Therapeutics, Handok Pharmaceutical Company, Janssen Korea, Novartis Korea<\/b> Other, Consulting fees. <br><b>T. Kim, <\/b> <br><b>AstraZeneca, MedImmune<\/b> Other, Trial funding. <br><b>Daiichi-Sankyo, HK inno.N, Janssen, Samsung Bioepis<\/b> Other, Consulting fees. <br><b>Amgen, AstraZeneca\/MedImmune, Boryung, IMBdx Inc., Janssen, Novartis, Regeneron, Roche\/Genentech, Takeda, Yuhan<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>M. Wang, <\/b> <br><b>Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genmab, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics<\/b> Grant\/Contract. <br><b>VelosBio, Vincerx<\/b> Grant\/Contract. <br><b>AbbVie, Acerta Pharma, ADC Therapeutics America, Amphista Therapeutics Limited, AstraZeneca, BeiGene, BioInvent, Bristol Myers Squibb, Deciphera, Genentech<\/b> Other, Consulting fees. <br><b>InnoCare, Janssen, Kite Pharma, Lilly, Merck, Miltenyi Biomedicine, Oncternal, Parexel, Pepromene Bio, Pharmacyclics, VelosBio<\/b> Other, Consulting fees. <br><b>AbbVie, Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Bristol Myers Squibb, CAHON, Catamount Medical Education, Dava Oncology, Genmab, Janssen, Kite Pharma<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>MJH Life Sciences, Merck, MSC National Research Institute of Oncolgy, NIH, Nurix, Pharmacyclics, Physicians Education Resources (PER)<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Research to Practice, Scripps, Studio ER Congressi, South African Clinical Hematology Society, WebMD<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>C. Hall, <\/b> <br><b>AstraZeneca<\/b> Stock, Travel, Other, Support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.). Support for attending meetings, other financial or non-financial interests. <br><b>F. Cader, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>K. Beyfuss, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock, Other, Support for attendance at ASH. <br><b>P. Cheung, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock, Other, Support for attending ASH and IMS. <br><b>W. Quan, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>S. Sharma, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock, Other, ASH Meeting. <br><b>Y. Marmor, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>J. Saeh, <\/b> <br><b>AstraZeneca<\/b> Employment.<br><b>J. Mariz, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11513","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"25","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT146","PresenterBiography":null,"PresenterDisplayName":"Janeen Nuttall","PresenterKey":"fa7eb4e6-45b7-4b77-832c-92fbc5862757","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT146. AZD0466 in patients with advanced non-Hodgkin lymphoma: Efficacy and safety in an open-label phase 1 trial","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"AZD0466 in patients with advanced non-Hodgkin lymphoma: Efficacy and safety in an open-label phase 1 trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"BTK,Small molecule inhibitor,Lymphoma,Lymphoma: non-Hodgkin's lymphoma,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>N. Lee<\/b>, Y. Li, Y. Mao, G. Liu, J. Li, Q. Liu; <br\/>Chengdu Hyperway Pharmaceuticals, Chengdu, China","CSlideId":"","ControlKey":"d2e1a3c7-b663-423f-93f5-d0247f49e364","ControlNumber":"9762","DisclosureBlock":"<b>&nbsp;N. Lee, <\/b> <br><b>Chengdu Hyperway Pharmaceuticals<\/b> Employment, Stock. <br><b>Y. Li, <\/b> <br><b>Chengdu Hyperway Pharmaceuticals<\/b> Employment, Stock, Patent. <br><b>Y. Mao, <\/b> <br><b>Chengdu Hyperway Pharmaceuticals<\/b> Employment, Stock. <br><b>G. Liu, <\/b> <br><b>Chengdu Hyperway Pharmaceuticals<\/b> Employment, Stock, Patent. <br><b>J. Li, <\/b> <br><b>Chengdu Hyperway Pharmaceuticals<\/b> Employment, Stock. <br><b>Q. Liu, <\/b> <br><b>Chengdu Hyperway Pharmaceuticals<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11514","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"26","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT147","PresenterBiography":"","PresenterDisplayName":"Ning Lee, PhD","PresenterKey":"d1493061-a010-4316-8acf-3267d1063099","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT147. Phase I clinical study of Bruton&#8217;s tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"612","SessionOnDemand":"False","SessionTitle":"Phase 0 and Phase I Clinical Trials","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I clinical study of Bruton&#8217;s tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL)","Topics":null,"cSlideId":""}]